Rassu G, Sorrenti M, Catenacci L, Pavan B, Ferraro L, Gavini E
Pharmaceutics. 2023; 15(6).
PMID: 37376027
PMC: 10305553.
DOI: 10.3390/pharmaceutics15061578.
Pardridge W
Pharmaceutics. 2022; 14(6).
PMID: 35745855
PMC: 9229021.
DOI: 10.3390/pharmaceutics14061283.
Pascoal V, Marchesini R, Athie M, Matos A, Conte F, Pereira T
Cell Mol Neurobiol. 2022; 43(1):367-380.
PMID: 35061107
DOI: 10.1007/s10571-022-01190-y.
Singh C, Eyford B, Abraham T, Munro L, Choi K, Okon M
Front Neurosci. 2021; 15:596976.
PMID: 34149342
PMC: 8212695.
DOI: 10.3389/fnins.2021.596976.
Leclerc M, Dudonne S, Calon F
Int J Mol Sci. 2021; 22(7).
PMID: 33805947
PMC: 8037419.
DOI: 10.3390/ijms22073356.
Immunotherapy for Medulloblastoma: Current Perspectives.
Kabir T, Kunos C, Villano J, Chauhan A
Immunotargets Ther. 2020; 9:57-77.
PMID: 32368525
PMC: 7182450.
DOI: 10.2147/ITT.S198162.
Magnetic Graphene Oxide Nanocarrier for Targeted Delivery of Cisplatin: A Perspective for Glioblastoma Treatment.
Makharza S, Cirillo G, Vittorio O, Valli E, Voli F, Farfalla A
Pharmaceuticals (Basel). 2019; 12(2).
PMID: 31109098
PMC: 6631527.
DOI: 10.3390/ph12020076.
Alterations in Cellular Processes Involving Vesicular Trafficking and Implications in Drug Delivery.
Muro S
Biomimetics (Basel). 2019; 3(3).
PMID: 31105241
PMC: 6352689.
DOI: 10.3390/biomimetics3030019.
Reduction-responsive PEtOz-SS-PCL micelle with tailored size to overcome blood-brain barrier and enhance doxorubicin antiglioma effect.
Li Y, Baiyang L, Leran B, Zhen W, Yandong X, Baixiang D
Drug Deliv. 2017; 24(1):1782-1790.
PMID: 29172749
PMC: 8241033.
DOI: 10.1080/10717544.2017.1402218.
Cyclic hexapeptide-conjugated nanoparticles enhance curcumin delivery to glioma tumor cells and tissue.
Zhang X, Li X, Hua H, Wang A, Liu W, Li Y
Int J Nanomedicine. 2017; 12:5717-5732.
PMID: 28848349
PMC: 5557616.
DOI: 10.2147/IJN.S138501.
Internalization of targeted quantum dots by brain capillary endothelial cells in vivo.
Paris-Robidas S, Brouard D, Emond V, Parent M, Calon F
J Cereb Blood Flow Metab. 2015; 36(4):731-42.
PMID: 26661181
PMC: 4820005.
DOI: 10.1177/0271678X15608201.
A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy.
Qin L, Wang C, Fan H, Zhang C, Zhang H, Lv M
Oncol Lett. 2014; 8(5):2000-2006.
PMID: 25289086
PMC: 4186501.
DOI: 10.3892/ol.2014.2449.
Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
Gaillard P, Appeldoorn C, Dorland R, van Kregten J, Manca F, Vugts D
PLoS One. 2014; 9(1):e82331.
PMID: 24416140
PMC: 3885379.
DOI: 10.1371/journal.pone.0082331.
Vascular Pathology as a Potential Therapeutic Target in SCI.
Benton R, Hagg T
Transl Stroke Res. 2013; 2(4):556-74.
PMID: 24323683
DOI: 10.1007/s12975-011-0128-7.
Challenges in design and characterization of ligand-targeted drug delivery systems.
Muro S
J Control Release. 2012; 164(2):125-37.
PMID: 22709588
PMC: 3481020.
DOI: 10.1016/j.jconrel.2012.05.052.
Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system.
Zdarova Karasova J, Zemek F, Musilek K, Kuca K
Neurotox Res. 2012; 23(1):63-8.
PMID: 22585538
DOI: 10.1007/s12640-012-9329-4.
Poly(ε-caprolactone)-block-poly(ethyl ethylene phosphate) micelles for brain-targeting drug delivery: in vitro and in vivo valuation.
Zhang P, Hu L, Wang Y, Wang J, Feng L, Li Y
Pharm Res. 2010; 27(12):2657-69.
PMID: 20848303
DOI: 10.1007/s11095-010-0265-9.
Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders.
Kang Y, Digicaylioglu M, Russo R, Kaul M, Achim C, Fletcher L
Ann Neurol. 2010; 68(3):342-52.
PMID: 20818790
PMC: 3733362.
DOI: 10.1002/ana.22070.
A novel transgenic zebrafish model for blood-brain and blood-retinal barrier development.
Xie J, Farage E, Sugimoto M, Anand-Apte B
BMC Dev Biol. 2010; 10:76.
PMID: 20653957
PMC: 2914679.
DOI: 10.1186/1471-213X-10-76.
